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Abstract: The design of nanoparticle delivery materials possessing biological activities is an
attractive strategy for the development of various therapies. In this study, 11 cationic amphiphilic
4-(N-alkylpyridinium)-1,4-dihydropyridine (1,4-DHP) derivatives differing in alkyl chain length
and propargyl moiety/ties number and position were selected for the study of their self-assembling
properties, evaluation of their cytotoxicity in vitro and toxicity on microorganisms, and the
characterisation of their interaction with phospholipids. These lipid-like 1,4-DHPs have been
earlier proposed as promising nanocarriers for DNA delivery. We have revealed that the mean
diameter of freshly prepared nanoparticles varied from 58 to 513 nm, depending upon the 4-(N-
alkylpyridinium)-1,4-DHP structure. Additionally, we have confirmed that only nanoparticles formed
by 4-(N-dodecylpyridinium)-1,4-DHP derivatives 3 and 6, and by 4-(N-hexadecylpyridinium)-
1,4-DHP derivatives 10 and 11 were stable after two weeks of storage. The nanoparticles of these
compounds were found to be homogenous in size distribution, ranging from 124 to 221 nm.
The polydispersity index (PDI) values of 1,4-DHPs samples 3, 6, 10, and 11 were in the range of
0.10 to 0.37. We also demonstrated that the nanoparticles formed by 4-(N-dodecylpyridinium)-
1,4-DHP derivatives 3, 6, and 9, and 4-(N-hexadecylpyridinium)-1,4-DHP derivatives 10 and 11 had
zeta-potentials from +26.07 mV (compound 6) to +62.80 mV (compound 11), indicating a strongly
positive surface charge and confirming the relative electrostatic stability of these nanoparticle
solutions. Transmission electron microscopy (TEM) images of nanoaggregates formed by 1,4-DHPs
3 and 11 confirmed liposome-like structures with diameters around 70 to 170 nm. The critical
aggregation concentration (CAC) value interval for 4-(N-alkylpyridinium)- 1,4-DHP was from
7.6 µM (compound 11) to 43.3 µM (compound 6). The tested 4-(N-alkylpyridinium)-1,4-DHP
derivatives were able to quench the fluorescence of the binary 1,6-diphenyl-1,3,5-hexatriene
Pharmaceutics 2019, 11, 115; doi:10.3390/pharmaceutics11030115 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2019, 11, 115 2 of 19
(DPH)—1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) system, demonstrating hydrophobic
interactions of 1,4-DHPs with phospholipids. Thus, 4-(N-dodecylpyridinium)-1,4-DHP derivative 3
quenched the fluorescence of the DPH–DPPC system more efficiently than the other 4-(N-
alkylpyridinium)-1,4-DHP derivatives. Likewise the compound 3, also 4-(N-dodecylpyridinium)-
1,4-DHP derivative 9 interacted with the phospholipids. Moreover, we have established that
increasing the length of the alkyl chain at the quaternised nitrogen of the 4-(N-alkylpyridinium)-
1,4-DHP molecule or the introduction of propargyl moieties in the 1,4-DHP molecule significantly
influences the cytotoxicity on HT-1080 (human fibrosarcoma) and MH-22A (mouse hepatocarcinoma)
cell lines, as well as the estimated basal cytotoxicity. Additionally, it was demonstrated that the
toxicity of the 4-(N-alkylpyridinium)-1,4-DHP derivatives on the Gram-positive and Gram-negative
bacteria species and eukaryotic microorganism depended on the presence of the alkyl chain length
at the N-alkyl pyridinium moiety, as well as the number of propargyl groups. These lipid-like
compounds may be proposed for the further development of drug formulations to be used in
cancer treatment.
Keywords: synthetic lipids; pyridinium and propargyl moieties; nanoparticles; self-assembling
properties; DLS; TEM; cytotoxicity; toxicity on microorganisms; phospholipid binding
1. Introduction
Over the past few decades, scientists worldwide have made efforts to expand the discovery
and development of a broad range of nanoparticle delivery systems. These studies had been
generally supported by the pharmaceutical and food industries as end-users. Liposomes have
been widely studied as perspective delivery systems due to their efficiency, biocompatibility, and
dual character—their ability to entrap either hydrophobic or hydrophilic drugs, improving their
pharmacokinetic and pharmacodynamic properties [1]. Synthetic nanoparticle-forming cationic
lipid-like compounds have been developed as delivery agents for the transfer of genetic materials,
including plasmid DNA (pDNA) molecules, into cells [2–4] and recently also for therapy and diagnostic
applications [5–8]. In general, among the synthetic cationic delivery systems, quaternary ammonium
surfactants are more toxic than their analogues, with the cationic charge delocalised in a heterocyclic
ring [9].
Diverse groups of nanoparticles have been reported to possess inherent antimicrobial
properties [10,11]. Also, the intrinsic antitumor activity of a carrier material based on cationic
lipids that have biguanide as a structural fragment have been reported [12]. Enhancement of the
therapeutic efficiency of anticancer agents by their incorporation into vitamin E-based delivery systems
is well-known approach with great potential [13–15]. The elaboration of nanoparticles that have
inherent biological properties may have potential in the future development of antimicrobial and/or
antitumor therapies [16,17].
Previously, our group elaborated and studied multiple liposomes forming cationic
1,4-dihydropyridine (1,4-DHP) amphiphiles, which were capable of transfecting pDNA into different
cell lines in vitro. For an evaluation of the molecule architecture influence on gene delivery properties,
various 1,4-DHP amphiphiles containing single or double cationic moieties were designed, synthesised,
and studied (Figure 1, groups 1 and 2).
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2. Materials and Methods
2.1. 4-(N-Alkylpyridinium)-1,4-Dihydropyridine (1,4-DHP) Derivatives
All of the 1,4-DHP derivatives (see Figure 2) provided for the studies have been synthesised
in the Laboratory of Membrane active compounds of the Latvian Institute of Organic Synthesis.
4-(N-Alkylpyridinium)-1,4-DHP derivatives were obtained according to the already reported methods:
1,4-DHP derivatives 1–6, 10, and 11 [22] and 1,4-DHP derivatives 7–9 [26].
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Figure 2. Structures of tested 4-(N-alkylpyridinium)-1,4-DHP derivatives 1–11 with variation of alkyl
chain length (A–D) and variation of number a d position of propargyl moiety (I–III).
Mass spectra were obtained on a Waters Acquity ultra performance liquid chromatography
(UPLC) system (Waters, Milford, MA, USA) connected to a Waters SQ Detector-2 operating in the
electrospray ionization (ESI) positive ion mode on a Waters Acquity UPLC® BEH C18 column (1.7 µm,
2.1 × 50 mm) using a gradient elution with MeCN (0.01% CF3CO2H) in water (0.01% CF3CO2H) at a
flow rate 0.5 mL/min and processed with the Waters MassLynx 4.1 chromatography data system [22,26].
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2.2. Cell Culture and Measurement of Cell Viability
Tumor cell lines HT-1080 (human connective tissue fibrosarcoma) and MH-22A (mouse
hepatocarcinoma) were used. All of the cells were obtained from the American Type Culture Collection
((ATCC,) Rockville, MD, USA).
HT-1080 and MH-22A cells (4× 104 cell/mL) were seeded in 96-well plates in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine serum and cultivated for 72 h at 37 ◦C, 5%
CO2 by exposure to different compounds concentrations (100 µg/mL, 25 µg/mL, 6.25 µg/mL, and
1.56 µg/mL). Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT) assay. In brief, after incubating with compounds, the culture medium was removed
and fresh medium with 0.2 mg/mL MTT was added in each well of the plate. After incubation (3 h,
37 ◦C, 5% CO2), the medium with MTT was removed, and 200 µL of DMSO was added at once to each
sample. The samples were tested at 540 nm on a Tecan multiplate reader Infinite1000 (Tecan Austria
GmbH, Salzburg, Austria). The IC50 was calculated using the program Graph Pad Prism® 3.0.
2.3. Basal Cytotoxicity Test
The neutral red uptake (NRU) assay was performed according to the standard protocol of
Stokes [27] modified by NICEATM-ECVAM validation study [28]. The NRU cytotoxicity assay
procedure was based on the ability of viable cells to incorporate and bind neutral red, which is
a supravital dye.
NIH 3T3 (Mouse Swiss Albino embryo fibroblast) cells (9000 cells/well) were placed into 96-well
plates for 24 h in DMEM medium containing 5% fetal bovine serum (FBS). Then, they were exposed
to the test compound over a range of seven concentrations (1000 µg/mL, 316 µg/mL, 100 µg/mL,
31 µg/mL, 10 µg/mL, 3.0 µg/mL, and 1.0 µg/mL) for 24 h. Untreated cells were used as a control.
After 24 h, the medium was removed from all plates. Then, 250 µL of neutral red (NR) solution was
added (0.05 mg/mL NR in DMEM 24 h pre-incubated at 37 ◦C and then filtered before use through
a 0.22-µm syringe filter). Plates were incubated for 3 h, and then, cells were washed three times
with phosphate buffered saline (PBS). The dye within viable cells was released by extraction with a
mixture of acetic acid, ethanol, and water (1:50:49). The absorbance of neutral red was measured using
a spectrophotometer multiplate reader Infinite M1000 (Tecan Austria GmbH, Salzburg, Austria) at
540 nm. The optical density (OD) was calculated using the formula: OD (treated cells) × 100/OD
(control cells). The IC50 values were calculated using the program Graph Pad Prism® 3.0.
2.4. Estimation of LD50 from IC50 Values
Data from the in vitro tests were used for estimating the starting dose for acute oral systemic
toxicity tests in rodent. The in vivo starting dose is an estimated LD50 value that is calculated by
inserting the in vitro IC50 value into a regression formula: log LD50 (mM/kg) = 0.439 log IC50 (mM)
+ 0.621 [29]. The value is recalculated to mg/kg, and compounds are evaluated in accordance with
four toxicity categories [30]: category 1: LD50 ≤ 5 mg/kg (highly toxic); category 2: 5 < LD50 ≤
50 mg/kg (moderately toxic); category 3: 50 < LD50 ≤ 300 mg/kg (slightly toxic); category 4: 300 <
LD50 ≤ 2000 mg/kg (practically non-toxic). Using an alternative in vitro method enables comparing
the possible toxicity of new compounds and selecting compounds for further study, which will vastly
reduce the number of animal experiments.
2.5. Toxicity Screen
An estimation of the toxicity of 4-(N-alkylpyridinium)-1,4-DHP derivatives 3, 6, 7, and 9–11
was performed using six prokaryotic (bacteria) and one eukaryotic (yeast) microorganism species
according to the procedure elaborated by Suppi et al. [31]. The microorganisms used in the study and
their origin were: Bacillus subtilis subsp. spizizenii (ATCC® 6633™*, Microbiologics®, St Cloud, MN,
USA), Escherichia coli (ATCC® 8739, Microbiologics®), Klebsiella pneumoniae (Latvian Microorganisms
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strain collection, LMKK, strain number 535, Riga, Latvia), Micrococcus luteus (LMKK, No. 25),
Pseudomonas aeruginosa (NCTC 12924, Biosciences Ltd., Dublin, Ireland), Proteus mirabilis (LMKK,
No 590), and Saccharomyces cerevisiae, CEN.PK2 strain [32].
2.6. Microorganism Cultivation and Toxicity Test
For toxicity screening, a compound serial dilution–spot test method as suggested by Suppi et al.
was used [31].
Bacteria and yeast cultures were cultivated until their exponential growth phase (optical density
max 1); then, 100 µL of cell suspension was taken, washed in deionised (DI) water, and added to
serially diluted samples of corresponding 4-(N-alkylpyridinium)-1,4-DHPs in DI water. All 1,4-DHPs
were tested in five serially diluted concentrations (10 mM, 1 mM, 0.1 mM, 0.01 mM, and 0.001 mM).
Test organisms were exposed to 1,4-DHP derivatives in DI water on 96-well microplates (Corning,
Corning, NY, USA) at 28 ◦C for 24 h without shaking in the dark. Then, a 5 µL sample was taken
from each well and spotted on yeast extract, bactopeptone, dextrose broth (YPD) (yeast extract 1%,
bactopeptone 2%, glucose 2% and agar 2%) plates to test the growth of yeasts and lysogeny broth (LB)
(yeast extract 0.5%, bactopeptone 1%, NaCl 0.5% and agar 2%) to test the growth for bacteria. Plates
were left in 30 ◦C for 24 h, and assessed for microbial growth.
Boundary concentration was defined as the last dilution of 1,4-DHP, which did not fully inhibit
the growth of microorganisms (colonies were present). If there were no colonies after incubation
with 1,4-DHPs in the last concentration of (0.001 mM), then their boundary concentration was set to
0.0001 mM or 0.1 µM.
The effects of 4-(N-alkylpyridinium)-1,4-DHP derivatives 3, 6, 7, and 9–11 on microbial survival
(boundary concentrations) were analysed by PCA (Principal Component Analyses) via online ClustVis
tool [33].
2.7. Phospholipid Binding Assay
Binding studies of the 4-(N-alkylpyridinium)-1,4-DHP derivatives 1–11 with phospholipid
were carried out in Tris-buffered saline (TBS) buffer (10 mM of Tris, 150 mM of NaCl, pH 7.4) by
a fluorescence probe technique using a modified protocol described by Ma et al. [34,35]. Briefly,
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) vesicles dispersed in TBS buffer were prepared
by sonication of the lipid solution using a probe sonifier for 30 min. The concentration of DPPC stock
solution was 6× 10−5 M; the concentration of the stock solutions of the 4-(N-alkylpyridinium)-1,4-DHP
derivatives were 1.5 × 10−4 M.
To characterise the hydrophobic interaction between the 1,4-DHP and phospholipids, 1,6-diphenyl-
1,3,5-hexatriene (DPH) was used as a fluorescence probe. The lipid-bound DPH shows intense
fluorescence at 440 nm (excitation, 368 nm), while the non-bound DPH does not exhibit fluorescence in
aqueous solution. DPH was used as a probe to determine the hydrophobic interaction between the
esters and the phospholipid. Stock solutions of DPH in acetone (15 × 10−4 M) were freshly prepared
and kept in the dark and diluted with TBS buffer (pH = 7.4) to concentration.
Mixtures containing 40 µL of DPPC stock solution (6 × 10−5 M) and 40 µL of DPH diluted
stock solution (15 × 10−6 M) were incubated at 50 ◦C for 0.5 h in the dark; then, an aliquot of
4-(N-alkylpyridinium)-1,4-DHP derivatives was added with the following incubation at 50 ◦C for
0.5 h in the dark, after which samples were cooled to room temperature and the fluorescence intensity
was measured by a Tecan multiplate reader Infinite1000 (Tecan Austria GmbH, Salzburg, Austria).
The final concentrations of compounds in the sample were: DPPC (2 × 10−5 M), DPH (5 × 10−6 M),
and 1,4-DHP 1–5, 7, and 9–11 (5 × 10−5 M).
2.8. Self-Assembling Properties by Dynamic Light Scattering Measurements
Samples of compounds for dynamic light scattering (DLS) studies were prepared by thin-film
hydration method in an aqueous solution at a concentration of 0.5 mg/mL for compounds 1–7,
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0.25 mg/mL for compounds 8–10, and 0.1 mg/mL for compound 11. A corresponding amount of
compounds was weighted in a round-bottom flask and dissolved in chloroform; then, the organic
solvent was removed in vacuo, and the residue was dried in high vacuo for 1 h. An appropriate
amount of deionised water was added to each flask for the preparation of stock solutions with the
above-mentioned concentrations. Samples were prepared by sonication using a bath-type sonicator
(Cole Parmer Ultrasonic Cleaner 8891CPX (Vernon Hills, IL, USA)). Samples were sonicated for 60 min
at 50 ◦C.
The DLS measurements of the nanoparticles in an aqueous solution were carried out on a
Zetasizer Nano ZSP (Malvern Panalytical Ltd., Malvern, UK) instrument with Malvern Instruments
Ltd. Software 7.12, using the following specifications—medium: water; refractive index: 1.33; viscosity:
0.8872 cP; temperature: 25 ◦C; dielectric constant: 78.5; nanoparticles: liposomes; refractive index of
materials: 1.60; detection angle: 173◦; wavelength: 633 nm. Data were analysed using the multimodal
number distribution software that was included with the instrument. The measurements were
performed in triplicate in order to check their reproducibility.
2.9. Determination of CAC
The critical aggregation concentrations (CAC) of 4-(N-alkylpyridinium)-1,4-DHP derivatives were
determined in aqueous media using a Zetasizer Nano S90 (Malvern Panalytical Ltd., Malvern, UK)
instrument with Malvern Instruments Ltd. Software according to procedure described by Topel et
al. and modified by our group [19,36]. Briefly, as stock solutions of tested compounds were used,
samples were prepared for self-assembling experiments. All of the subsequent samples were prepared
starting from the concentrated stock solution, which was subjected to a serial two-fold dilution each
time with water. The intensity values of scattered light (kcps) as a function of concentration of
amphiphiles were analysed. The scattering intensities detected for amphiphile concentrations below
CAC have an approximately constant value corresponding to water. The intensity starts to show
a linear increase with concentration at the CAC, since the amount of nanoparticles increases in the
solution. The intersection of the best-fit lines drawn through the data points is the preliminary CAC
value of the compounds.
2.10. Transmission Electron Microscopy (TEM)
The morphology of nanoparticles formed by selected 4-(N-alkylpyridinium)-1,4-DHP derivatives
3 and 11 (0.15 mM) was studied by TEM. Negative stained TEM samples were prepared using the side
blotting method. The sample solution was placed on a carbon-coated grid (Agar AGS160-4); excess
solution was drained with filter paper, and then it was negatively stained with 2% uranyl acetate,
which was freshly prepared and filtered with a 0.22-µm filer. TEM measurements were performed
using Tecnai G2 F20 (FEI, Hillsboro, OR, USA) microscope at 60 kV.
2.11. Statistical Analysis
Results are expressed as mean standard deviation (SD). All of the experiments were performed
in triplicate.
3. Results and Discussion
3.1. 4-(N-Alkylpyridinium)-1,4-Dihydropyridine Derivatives
The synthesis of selected 4-(N-alkylpyridinium)-1,4-dihydropyridine derivatives 1–11 differing
in alkyl chain length and propargyl moiety/ties number and position was carried out by previously
described methods [22,26]. Briefly, the 1,4-DHP derivatives were synthesised via typical synthetic
routes, including the classical Hantzsch method [37], which involved the one-pot cyclocondensation
of the corresponding esters of acetoacetic acid, and the corresponding aldehyde and ammonia or
ammonium acetate as a nitrogen source in ethanol under reflux. The N-propargyl-substituted 1,4-DHP
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derivatives were obtained by analogy with the synthesis of other N-substituted 1,4-DHP ones via
a modified Hantzsch-type cyclisation using propargyl amine hydrochloride as a nitrogen source
instead of ammonia and pyridine as a solvent under reflux. The synthesis of all the 4-pyridinium
moieties containing 1,4-DHP derivatives were performed by the alkylation of 4-pyridyl-1,4-DHP
derivatives with the corresponding alkyl bromides in acetone under reflux. The typical procedure
for the quaternisation of pyridyl-1,4-DHP derivatives was performed in analogy with the procedure
described by Makarova et al. [38,39].
In order to evaluate the influence of the pharmacophore group on the structure–activity
relationship, 11 1,4-DHP derivatives were divided into two groups considering structure elements
(see Figure 2):
1. 1,4-DHP derivatives with different lengths of alkyl moieties at the quaternised nitrogen atom at
the position 4 of the 1,4-DHP ring (Figure 2, rows A–D):
1.1. 4-(N-Ethylpyridinium)-1,4-DHP derivatives (compounds 1, 4, 7);
1.2. 4-(N-Hexylpyridinium)-1,4-DHP derivatives (compounds 2, 5, 8);
1.3. 4-(N-Dodecylpyridinium)-1,4-DHP derivatives (compounds 3, 6, 9);
1.4. 4-(N-Hexadecylpyridinium)-1,4-DHP derivatives (compounds 10, 11).
2. 1,4-DHP derivatives without or with shifted propargyl moiety/ies (Figure 2, columns I, II, III):
2.1. 1,4-DHP derivatives without propargyl moiety/ies (compounds 1–3 and 10);
2.2. Propargyl moiety at the position 1 of the 1,4-DHP ring (1-propargyl-4-(N-alkylpyridyl)-1,4-
DHP; compounds 4–6, 11);
2.3. Propargyl moieties at the positions 3 and 5 of the 1,4-DHP ring (bispropargyl 4-(N-
alkylpyridinium)-1,4-DHP 3,5-dicarboxylates; compounds 7–9).
The purities of the studied compounds were at least 97% according to high-performance liquid
chromatography (HPLC) data. The detailed synthetic procedures, yields of products, nuclear magnetic
resonance (NMR) spectrum data for 4-(N-alkylpyridinium)-1,4-dihydropyridine derivatives 1–11 were
described by Rucins et al. [22,26].
3.2. Estimation of LD50 from IC50 Values
Antiproliferative activity and also a potential toxic effect were evaluated for 4-(N-
alkylpyridinium)-1,4-DHP derivatives 1–9. Currently, it is recommendable to start toxicology studies
with preliminary in vitro estimation before using animal models [40]. It has been proposed that the
equation from the correlation of IC50 (the concentration of a substance that causes 50% toxicity in vitro)
could be applied to estimate unknown LD50 values for a new compound from IC50 values measured as
basal cytotoxicity in vitro. This estimated LD50 gives prior information regarding compound properties
and would be used to select promising compounds and a starting dose for in vivo experiments.
The evaluation of cytotoxicity of 4-(N-alkylpyridinium)-1,4-DHP derivatives 1–9 in vitro was
assessed using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay on two monolayer tumor cell lines, namely HT-1080 (human fibrosarcoma) and MH-22A (mouse
hepatocarcinoma). Additionally, the compound influence on “normal” mouse fibroblasts (NIH 3T3)
was estimated for the studies of structure–activity relationships and exploration of the effect of
substituents. The results are presented in Table 1.
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Table 1. Comparison of cytotoxicity, estimated basal cytotoxicity of 4-(N-alkylpyridinium)-1,4-DHP
derivatives 1–9.
Comp.
Cytotoxicity IC50, µM Basal Cytotoxicity Estimated a LD50
HT-1080 MH-22A mM/kg mg/kg
1 ne ne 5.8 ± 0.3 2548
2 26 ± 2 67 ± 4 2.8 ± 0.3 1404
3 37 ± 2 15 ± 1 1.2 ± 0.4 692
4 ne ne 4.8 ± 0.1 2280
5 5 ± 0.3 16 ± 1 1.3 ± 0.4 669
6 4 ± 0.4 1 ± 0.2 0.3 ± 0.1 183
7 ne ne >6 >2710
8 76 ± 8 80 ± 5 2.2 ± 0.4 1165
9 2 ± 0.2 1 ± 0.2 0.5 ± 0.05 300
a Estimated LD50 was calculated based on IC50 (mM) value from NIH 3T3 cells Neutral Red Uptake assay (NRU)
assay using the regression formula: log LD50 (mM/kg) = 0.439 log IC50 (mM) + 0.621 [29]. Ne—no effect in the
tested concentration.
The obtained data showed that 4-(N-ethylpyridinium)-1,4-DHP derivatives 1, 4, and 7 did not
demonstrate any cytotoxic effect on tumor HT-1080 and MH-22A cell lines, and their estimated toxicity
LD50 was defined as practically non-toxic (basal cytotoxicity LD50 ≥2000 mg/kg); LD50 values for
compounds 1, 4, and 7 are 2548, 2280 and >2710, respectively. In contrast, 4-(N-hexylpyridinium)-
1,4-DHP derivatives 2, 5, and 8 and 4-(N-dodecylpyridinium)-1,4-DHP derivatives 3, 6, and 9 possessed
cytotoxicity on tumor cell lines (IC50 1–80 µM) and their estimated LD50 was defined as slightly toxic
(183 mg/kg and 300 mg/kg for compound 6 and 9, respectively) or non-toxic (1404, 692, 669, and
1165 for 1,4-DHP derivatives 2, 3, 5, and 8, respectively). Very pronounced cytotoxicity was observed
for 1-propargyl substituted 4-(N-hexylpyridinium)-1,4-DHP derivative 5 (IC50 5 µM in the HT-1080)
and also for 1-propargyl substituted 4-(N-dodecylpyridinium)-1,4-DHP derivative 6 and bispropargyl
4-(N-dodecylpyridinium)-1,4-DHP 3,5-dicarboxylate 9, where IC50 values were in the range of 1 to 4 µM
in the both cell lines. Meanwhile, IC50 values in the both cell lines were in the range of 15 to 80 µM
for 4-(N-hexylpyridinium)-1,4-DHP 2 and 4-(N-dodecylpyridinium)-1,4-DHP 3, both compounds
without propargyl moieties, bispropargyl 4-(N-hexylpyridinium)-1,4-DHP 3,5-dicarboxylate 8, and
only in the MH-22A cell line for 1-propargyl substituted 4-(N-hexylpyridinium)-1,4-DHP derivative
5. Our observation suggests that increasing the length of the alkyl chain from ethyl to dodecyl at
the quaternised nitrogen atom at position 4 of the 1,4-DHP significantly increases the cytotoxicity
as well as the estimated basal cytotoxicity of compounds (1 versus 2 versus 3 and 4 versus 5 versus
6 and 7 versus 8 versus 9: 2548/1404/692 and 2280/669/183 mg/kg and >2700/1165/300 mg/kg,
respectively (Table1)). Additionally, it was observed that the introduction of propargyl moiety/moieties
in the 1,4-DHP molecule also increased the basal cytotoxicity of 4-(N-hexylpyridinium)-1,4-DHP and
4-(N-dodecylpyridinium)-1,4-DHP derivatives, especially at position 1 of the 1,4-DHP cycle (2 versus
5 and 8; 3 versus 6 and 9: 1404/669 and 1165 mg/kg; 692/183 and 300 mg/kg, respectively (Table 1)).
Generally, it can be concluded that increasing the length of the alkyl chain from ethyl to dodecyl
at the quaternised nitrogen atom at position 4 of the 1,4-DHP ring or the introduction of propargyl
moiety/moieties into the 1,4-DHP molecule influences both the cytotoxicity against cancer cells and
also the estimated basal cytotoxicity of tested 4-(N-alkylpyridinium)-1,4-DHP derivatives.
3.3. Toxicity Test
Several different species of microorganisms were chosen to evaluate toxicity of 4-(N-alkylpyridinium)-
1,4-DHP derivatives 3, 6, 7, and 9–11 on microorganisms according to the procedure elaborated by
Suppi et al. [31]. The panel of microorganisms was composed based on an ecotoxicological review by
Egorova and Ananikov [38]. It included representatives of Gram-positive bacteria species (B. subtilis
and M. luteus) and representatives of Gram-negative bacteria species (E. coli, P. miriabilis, P. aeroginosa,
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and K. pneumoniae) and one example of eukaryotic microorganism (S. cerevisiae). The obtained results
(see Table S1 in the Supplementary Material) regarding the effect of 4-(N-alkylpyridinium)-1,4-DHP
derivatives 3, 6, 7, and 9–11 on microbial survival were analysed by Principle Component Analyses
(PCA) using the online ClustVis tool [33]. PCA is a mathematical procedure that reduces the
dimensionality of large datasets, increasing their interpretability while at the same time minimizing
information loss. Currently, PCA is one of the most important and powerful methods for standard
statistical tests in biology, medicine, and other fields using statistical tests [41,42]. In our studies, PCA
were used to evaluate how the influence of the molecular parameters (the presence of a propargyl
group and/or length of the alkyl chain) of the 4-(N-alkylpyridinium)-1,4-DHP derivatives affected their
toxicity in the tested microorganism panel. The boundary concentrations from the chosen 1,4-DHP
derivatives that were tested in all the microorganisms were collected in a score matrix (Table S1 in
the Supplementary Material), and the obtained data resulted in a four-dimension matrix (number of
propargyl groups; side chain length; microorganism; boundary concentration).
The 4-(N-ethylpyridinium)-1,4-DHP 7 did not affect the survival of microorganisms in the whole
range of the concentrations tested (10 to 0.001 mM). Similarly, this derivative turned out to be non-toxic
to the tested cancer cell lines also. On the contrary, other tested 1,4-dihydropyridine derivatives
containing N-dodecylpyridinium (compounds 3, 6, and 9) or N-hexadecylpyridinium (compounds 10
and 11) moieties were toxic at various degrees, affecting the viability of the microorganisms. A similar
relationship was observed also for ionic liquids (ILs): the increase in the length of the alkyl chain on
the ILs’ heterocyclic ring significantly increased their toxicity in most test systems [43,44]. To evaluate
the patterns of 4-(N-alkylpyridinium)-1,4-DHP alkyl chain effect on the survival of microorganisms
PCA were carried out using each compound boundary concentrations for each microorganism. The
obtained data are presented in Figure 3.
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find out hich of the parameters (number of propargyl groups and/or side chain length) has the
most significant impact on the compound’s toxicity, the “artificial” set of variables that would help to
visualise the main effects of data variance across a two-dimensional (2D) plot was sought. The data were
analysed and visualised by online tool ClustVis [33]. Vector scaling is applied to rows; the Nonlinear
Iterative Partial Least Squares (NIPALS) algorithm is used to calculate principal components [42]. The
scores of individual compound’s toxicities are plotted using the first two principal components, which
explain most of the variance (PC1 63.3% and PC2 19.3% for A, and 39.8% and 24.7% for B). Green
triangle: 4-(N-ethylpyridinium)-1,4-DHP 7.
Data for the set of tested 4-(N-alkylpyridinium)-1,4-DHP derivatives and their toxicities (Table S1
in Supplementary Material), indicated that compounds were rather scattered across a two-dimensional
(2D) plot with no pattern clustering neither with respect to the number of propargyl groups and
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alkyl chain length at alkylpyridinium moiety/ies. The toxicity of 4-(N-ethylpyridinium)-1,4-DHP
7 substantially differs from the toxicities of N-dodecylpyridinium (compounds 3, 6, and 9) or
N-hexadecylpyridinium (compounds 10 and 11) derivatives (Figure 3A). However, if compound
7 was omitted from PCA analyses, it can be concluded that 4-(N-alkylpyridinium)-1,4-DHPs were
grouped mainly based on their N-alkyl chain length rather than the number of propargyl groups
(Figure 3B).
Therefore we assume that the toxicity of the compound depends on the N-alkyl chain length at
the pyridinium moiety and/or the number of propargyl groups.
According to the literature data in microorganism assays, the tested toxicity of various cationic
surfactants that are capable of forming nanoaggregates were dependent on the alkyl chain length.
Thus, the values of IC50 for liposomes formed by hexadecyltrimethylammonium bromide and
didodecyldimethylammonium bromide were higher than the IC50 values for liposomes formed
by dioctadecyldimethylammonium bromide [45]. In our experiments, it was demonstrated that 4-(N-
dodecylpyridinium)-1,4-DHPs (compounds 3, 6, and 9) were more toxic than other 4-(N-alkylpyridinium)-
1,4-DHPs, such as 4-(N-ethylpyridinium)-1,4-DHP 7 and 4-(N-hexadecylpyridinium)-1,4-DHPs
(compounds 10 and 11).
3.4. Phospholipid Binding Assay
Lipid bilayers are essential in the regulation of in vivo barriers, and surfactants are known to
influence their organization and permeability [46]. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine
(DPPC) is a major membrane-forming phospholipid [47] in cell membranes, and is also widely used as
a model membrane to provide valuable information regarding the interaction of cell membranes and
lipids [48] and other various surfactants as antibacterial agents [49]. Therefore, in order to estimate the
potential impact of 4-(N-alkylpyridinium)-1,4-DHP derivatives on microorganisms, the binding assay
of DPPC with the cationic 1,4-DHP derivatives were performed.
DPPC bound to 1,6-diphenyl-1,3,5-hexatriene (DPH) shows enhanced fluorescence intensity at
440 nm (excited at 368 nm). According to the literature data, DPH interacts with DPPC through
hydrophobic interaction, and compounds are also capable of binding with the phospholipids through
hydrophobic interactions to quench the fluorescence of the lipid–DPH solution due to the competitive
binding mechanism [34]. In this work, DPH was used as a fluorescent probe to characterise the
interaction between the phospholipids and 4-(N-alkylpyridinium)-1,4-DHP derivatives.
According to obtained data (Figure 4), 4-(N-alkylpyridinium)-1,4-DHP derivatives quenched
the fluorescence of the DPPH–DPH solution. The decrease of sample fluorescence in the presence
of 1,4-DHPs indicated that 4-(N-alkylpyridinium)-1,4-DHPs were bound to the model membrane
near the DPH binding sites. The 4-(N-alkylpyridinium)-1,4-DHP derivatives were able to quench the
fluorescence of the binary DPH–DPPC, confirming that the tested 4-(N-alkylpyridinium)-1,4-DHP
derivatives 1–5 and 8–11 interact with the phospholipids via hydrophobic interactions in the order
of 3 > 9 > 11 > 7 ≥ 1 ≥ 10 ≥ 2 > 5 ≥ 4. We failed to obtain comparable data for the influence of
4-(N-dodecylpyridinium)-1,4-DHP derivative 6 interaction on the binary DPH–DPPC system; therefore,
the data for compound 6 was not included in Figure 4. In the case of 4-(N-dodecylpyridinium)-1,4-DHP
derivative 3, the lowest relative fluorescence intensity was demonstrated, which confirmed the ability
of this compound to quench the fluorescence of the DPH–DPPC system more efficiently than the other
4-(N-alkylpyridinium)-1,4-DHPs. Also, the ability of the 4-(N-dodecylpyridinium)-1,4-DHP derivative
9 to quench the fluorescence of the DPH–DPPC system can be compared with the one obtained for
compound 3. Our previous data showed that 4-(N-hexadecylpyridinium)-1,4-DHP derivative 10 and
structurally related compounds caused the remarkable release of calcein from DPPC liposomes and
induced the hemolysis of human erythrocytes, which confirmed correlation between the length of the
alkyl moiety at N-quaternised 4-pyridyl-1,4-DHP and the improvement of membranotropic effects
such as incorporation in the liposomal membranes and bilayer fluidity [25].
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Table 2. Values of critical aggregation concentration (CAC), the mean diameter (Dmean), zeta-potential,
and polydispersity index (PDI) of nanoparticles formed by 4-(N-alkylpyridinium)-1,4-DHP derivatives
1–11 obtained by dynamic light scattering (DLS) measurements. Final compound concentrations were
0.5 mg/mL for compounds 1–7, 0.25 mg/mL for compounds 8–10, and 0.1 mg/mL for compound 11.
The mean diameter (Dmean) depicts the hydrodynamic diameter of the main population of nanoparticles
in the tested sample; the PDI value describes polydispersity of the sample; the zeta-potential gives
information about the surface charge of nanoparticles. CAC is the concentration above which micelles
and other nanoparticles are formed.
Comp. Mw a
CAC,
µM
Zeta-Pot b. ±
SD, mV
PDI± SD Dmean ± SD, nm (%)
1 Set c 2 Set d 1 Set c 2 Set d
1 359 - −8.43 ± 2.14 0.18 ± 0.01 0.40 ± 0.16 58 ± 24 (98) 195 ± 75 (59)45 ± 13 (41)
2 415 - −11.39 ± 1.85 0.50 ± 0.10 0.91 ± 0.10 142 ± 24 (95) 225 ± 25 (100)
3 499 9.3 +57.73 ± 2.30 0.14 ± 0.01 0.17 ± 0.02 124 ± 51 (100) 140 ± 64 (100)
4 397 - −5.47 ± 1.97 0.16 ± 0.02 0.41 ± 0.07 79 ± 29 (99) 238 ± 76 (78)55 ± 19 (22)
5 453 - −9.96 ± 0.72 0.72 ± 0.32 0.59 ± 0.01 513 ± 55 (78) 503 ± 66 (100)
6 537 43.3 +26.07 ± 0.78 0.15 ± 0.02 0.20 ± 0.01 154 ± 64 (100) 184 ± 97 (100)
7 379 - −0.78 ± 0.26 0.90 ± 0.03 0.73 ± 0.09 258 ± 33 (100) 185 ± 24 (100)
8 435 - - 0.60 ± 0.06 0.45 ± 0.05 325 ± 50 (100) 330 ± 49 (100)
9 519 9.3 +32.00 ± 4.81 0.36 ± 0.08 0.57 ± 0.05 65 ± 21 (73)297 ± 78 (26)
415 ± 88 (98)
58 ± 7 (2)
10 555 28.2 +49.70 ± 7.94 0.10 ± 0.06 0.25 ± 0.05 221 ± 15 (100) 199 ± 73 (100)
11 593 7.6 +62.80 ± 0.78 0.37 ± 0.03 0.33 ± 0.03 145 ± 7 (91)51 ± 5 (9)
143 ± 43 (96)
41 ± 9 (4)
a Exact mass of compounds determined by mass spectrometry (MS): electrospray ionization positive ion mode
(+ESI) m/z (79Br) ([M–Br]+ [22,26]. b zeta-potential determined for freshly prepared samples. c First set: for freshly
prepared samples. d Second set: Two weeks after the first set; samples stored at r.t.
Additionally, the results showed a rather broad particle size distribution for compounds 2, 5,
7, and 8, possessing PDIs for the first set samples of 0.50, 0.72, 0.90, and 0.60, respectively. The
obtained data for all the 4-(N-hexylpyridinium)-1,4-DHP derivatives 2, 5, and 8 and bispropargyl
4-(N-ethylpyridinium)-1,4-DHP 3,5-dicarboxylate 7 confirmed the evidence of highly heterogeneous
samples from both of the measurement sets. The evaluation of nanoparticles formed by 4-(N-
alkylpyridinium)-1,4-DHP derivatives 2, 5, 7, and 8 with broad particle size distribution will not
be discussed further here, because these compounds are not perspective.
The PDI value was 0.36 for a freshly prepared sample of bispropargyl 4-(N-dodecylpyridinium)-
1,4-DHP 3,5-dicarboxylate 9; however, the sample contained two main populations of nanoparticles
with mean diameters 65 nm and 297 nm in the ratio 1:3 (Table 2). The similar PDI value of
0.37 was observed also for a freshly prepared sample of N-propargyl moiety containing 4-(N-
hexadecylpyridinium)-1,4-DHP derivative 11. This sample contained two main populations of
nanoparticles with mean diameters of 145 nm and 51 nm in the ratio of 10:1 (Table 2). The most
homogeneous particles were formed by 4-(N-alkylpyridinium)-1,4-DHP derivatives 1, 3, 4, 6, and 10
with PDI values of 0.18, 0.14, 0.16, 0.15, and 0.10, respectively.
Values of the zeta-potential of nanoparticles formed by 4-(N-alkylpyridinium)-1,4-DHP derivatives
1–11 were determined by DLS (Table 2). The obtained data indicated that nanoparticles formed
by 4-(N-dodecylpyridinium)-1,4-DHPs (compounds 3, 6, and 9) and 4-(N-hexadecylpyridinium)-
1,4-DHPs (compounds 10 and 11) had zeta-potentials from +26.07 mV (compound 6) to +62.80 mV
(compound 11), indicating a strongly positive surface charge (Table 2), while the values of the
zeta-potential of nanoparticles formed by 4-(N-ethylpyridinium)-1,4-DHPs (compounds 1, 4, and
6) and 4-(N-hexylpyridinium)-1,4-DHPs (compounds 2 and 5) were slightly negative (interval from
−0.78 mV (compound 7) until −9.96 mV (compound 5). Zeta-potentials over >±20 mV confirmed that
the formed nanoparticle solutions were also relatively electrostatically stable [50].
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For the evaluation of the stability of nanoparticles, the second set of measurements was undertaken
after two weeks of storage (samples were stored at r.t. between sets). It was found that the samples of
4-(N-ethylpyridinium)-1,4-DHP derivatives 1 and 4 and 4-(N-dodecylpyridinium)-1,4-DHP derivative
9 lost their homogeneity after two weeks of storage (Table 2). For these compounds, the PDI values
were increased to 0.40, 0.41, and 0.57, respectively, compared to the initial values of 0.18, 0.16,
and 0.36. The main point to be noted is that the measurements demonstrated the homogeneity
of the particles, which were composed of 4-(N-dodecylpyridinium)-1,4-DHP derivatives 3, 6 and
4-(N-hexadecylpyridinium)-1,4-DHP derivative 10. Thus, after two weeks of storage, the PDI values
were 0.17, 0.20, and 0.25, respectively. The sample for 4-(N-hexadecylpyridinium)-1,4-DHP derivative
11 maintained constant characteristic parameters: PDI values 0.37 and 0.33, and mean diameters of
145 nm (91%) and 143 (96%), respectively. The obtained data confirmed the stability of nanoparticles
formed by 1,4-DHP derivatives 3, 6, 10, and 11 after two weeks of storage.
For self-assembling compounds, the concentration above which micelles and other nanoparticles
are formed, which is called the critical aggregation concentration, is an important property. In this
study, CAC was determined for 4-(N-alkylpyridinium)-1,4-DHP derivatives 1–7 and 9–11 by the
DLS measurement. A representative example of the determination of CAC for 1,4-DHP 11 is
presented at Figure S1 in the Supplementary Material. The determined CAC values for tested
4-(N-alkylpyridinium)-1,4-DHP derivatives 3, 6, and 9–11 were in intervals from 7.6 µM (compound
11) to 43.3 µM (compound 6) (Table 2). CAC values for 4-(N-ethylpyridinium)-1,4-DHP derivatives
1, 4, 7, and 4-(N-hexylpyridinium)-1,4-DHP derivatives 2 and 5 cannot be determined clearly. An
unclear CAC and negative and low zeta-potential value (interval from −0.78 mV until −9.96 mV) of
particles formed by 4-(N-alkylpyridinium)-1,4-DHP derivatives 1, 2, 4, 5, and 7 also confirmed the
weak stability of the nanoparticles formed by these compounds. Our previous data showed that the
CAC values of double pyridinium moieties containing 1,4-DHP derivatives (Figure 2, Group 2) were
in the range of 7 to 35 µM, depending on nature of substituents [19,51]. The obtained data of CAC
has indicated that the increase of the N-alkyl chain length at the pyridinium moiety in the 1,4-DHP
molecule decreased the CAC value. For 4-(N-dodecylpyridinium)-1,4-DHP derivative 3, the CAC
value is comparable with the concentration of a substance that causes 50% toxicity in vitro (IC50) on
HT-1080 and MH-22A cell lines. It suggests that in this concentration, the cytotoxicity was estimated
as the cytotoxicity of nanoparticles.
The obtained results confirmed that the presence of a cationic charge and N-dodecylpyridinium
or N-hexadecylpyridinium moiety at the 1,4-DHP cycle was essential for the formation of stable
nanoparticles (3 versus 1 and 2; 6 versus 4 and 5) with mean diameter values in the rage of 124 to 184 nm
(4-(N-dodecylpyridinium)-1,4-DHPs 3 and 6); 145 to 221 nm (4-(N-hexadecylpyridinium)- 1,4-DHPs
10 and 11) (Table 2). Additionally, the introduction of propargyl moieties at positions 3 and 5 of the
1,4-DHP ring decreased the homogeneity and stability of the formed nanoparticles by bispropargyl
4-(N-dodecylpyridinium)-1,4-DHP 3,5-dicarboxylate 9 if compared to 4-(N-dodecylpyridinium)-
1,4-DHP 3 and 1-propargyl-(N-dodecylpyridinium)-1,4-DHP 6 (Table 2).
3.6. Transmission Electron Microscopy (TEM)
Morphology of the samples of nanoaggregates formed by selected 4-(N-dodecylpyridinium)-
1,4-DHP 3 and 1-propargyl-4-(N-hexadecylpyridinium)-1,4-DHP 11 was studied using transmission
electron microscopy (TEM) techniques. Representative TEM images of samples are given in Figure 5.
According to the obtained data, both samples contained spherical particles that were almost
spherical in shape, with the diameters ranging in the interval from 70 to 170 nm. The obtained
TEM data is also in agreement with the DLS measurement results, which enable making an
assumption that the nanoparticles that are formed by selected 4-(N-dodecylpyridinium)-1,4-DHP
3 and 4-(N-hexadecylpyridinium)-1,4-DHP 11 are liposome-like structures.
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grids and negatively stained with freshly prepared 2% uranyl acetate aqueous solution. The stock
sa ples were prepared by the thin-film hydration method following sonication in an aqueous solution
at 1,4-DHP concentrations of 0.5 mM (compound 3) and 0.15 mM (compound 11).
4. Conclusio s
The obtained results reveal that a variation of alkyl moiety lengths for the quaternised nitrogen
atom at position 4 of the 1,4-DHP cycle and the propargyl moiety number and position in the
4-(N-alkylpyridinium)-1,4-DHP molecule strongly affects the self-assembling properties of compounds
and characteristic parameters, and the stability of formed nanoparticles, as well as the toxicity of
tested lipid-like 1,4-DHP derivatives. It is shown that 4-(N-ethylpyridinium)-1,4-DHP derivatives 1, 4,
and 7 do not exhibit a cytotoxic effect on tumor HT-1080 and MH-22A cell lines. The estimated basal
cytotoxicity (LD50) of 4-(N- thy pyridinium)-1,4-DHP derivatives is defined as practically non-t xic.
Meanwhile, 4-(N-hexylpyridinium)-1,4-DHPs (2, 8, and 8) and 4-(N-dodecylpyrid nium)-1,4-DHP
derivatives (3, 6, and 9) possess cytotoxicity on tumor cell lin s (IC50 1–80 µM), and he estimated basal
cytotoxicity (LD50) of the compounds i defined as slightly toxic or non-toxic. Also, the toxicity
evaluated on Gram-positive and Gram-negative b cteria species and eukaryotic microorgani m
demonstrated th difference between 4-(N-ethylpyridinium)-1,4-DHP 7 and ong r alkyls, such as
4-(N-dodecylpyridinium)-1,4-DHP derivatives 3, 6, and 9 and 4-(N-h xadecylpyridinium)-1,4-DHP
der vatives 10 and 11.
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It can be concluded that the presence of N-dodecylpyridinium moiety and N-hexadecylpyridinium
moiety at the 1,4-DHP cycle is essential for the formation of stable nanoparticles with mean
diameter values in the range of 124 to 221 nm. However, the introduction of propargyl moieties
at positions 3 and 5 of the 1,4-DHP ring decreases the stability and homogeneity of the formed
nanoparticles. The obtained TEM data enables the suggestion that the nanoparticles formed by
the selected 4-(N-dodecylpyridinium)-1,4-DHP 3 and 4-(N-hexadecylpyridinium)-1,4-DHP 11 are
liposome-like structures.
The 4-(N-alkylpyridinium)-1,4-DHP derivatives quenched the fluorescence of the DPH of the
binary DPH–DPPC system, confirming hydrophobic interaction with the phospholipids. 4-(N-
Dodecylpyridinium)-1,4-DHP derivatives 3 and 9 quenched the fluorescence of the DPH–DPPC system
more efficiently than the other 4-(N-alkylpyridinium)-1,4-DHPs. These findings are highly important,
since 4-(N-dodecylpyridinium)-1,4-DHP 3 has already been reported to efficiently cross the blood–brain
barrier, block brain calcium channels, and improve memory by enhancing the GABAergic and synaptic
plasticity processes as well as influencing the levels of brain proteins, which contributes to synaptic
plasticity [24]. After more detailed studies, some of these lipid-like 4-(N-dodecylpyridinium)-1,4-DHP
derivatives can be proposed for use in cancer therapy as nanocarriers with intrinsic cytotoxic activity.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/3/115/s1,
Table S1: Toxicity test data of tested 4-(N-alkylpyridinium)-1,4-DHPs 3, 6, 7, and 9–11 on microorganism species;
Figure S1: Representative example of determination of critical aggregation concentration (CAC) by DLS technique
for 4-(N-hexadecylpyridinium)-1,4-DHP derivative 11.
Author Contributions: A.P. and A.S. conceived and designed the experiments; M.R., K.P. (Klavs Pajuste) and M.P.
performed the re-synthesis of compounds; P.D., O.P. and K.P. (Karlis Pajuste) performed experiments by DLS;
A.G., L.J. and I.D. performed the estimation of LD50 from IC50 values; S.K. and J.L. performed the toxicity tests on
microorganisms; K.P. (Klavs Pajuste), P.D. and K.P. (Karlis Pajuste) performed the determination of CAC; P.D.
performed the phospholipid binding assay; K.S. registered the TEM images; K.P. (Karlis Pajuste), P.D., M.P., D.T.,
J.L., I.D. and A.P. analysed the data; D.T. and A.S. contributed reagents/materials tools; and A.P. and A.S. wrote
the paper.
Funding: This research was funded by the EuroNanoMed2 project INNOCENT, PostDoc project Synthesis of
new magneto-active functional nanomaterials (1.1.1.2/VIAA/1/16/018) (for O.P.), PostDoc project Molecular
mechanisms of purine and pyrimidine auxotrophic starvation in budding yeast (YEAUX) (1.1.2/1/16/067) (for
J.L.) and scientific grant from the Student Council of University of Latvia (for S.K.).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Deshpande, P.P.; Biswas, S.; Torchilin, V.P. Current trends in the use of liposomes for tumor targeting.
Nanomedicine 2013, 8, 1509–1528. [CrossRef] [PubMed]
2. Felgner, P.L.; Gadek, T.R.; Holm, M.; Roman, R.; Chan, H.W.; Wenz, M.; Northrop, J.P.; Ringold, G.M.;
Danielsen, M. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad.
Sci. USA 1987, 84, 7413–7417. [CrossRef] [PubMed]
3. De Smedt, S.C.; Demeester, J.; Hennink, W.E. Cationic polymer based gene delivery systems. Pharma Res.
2000, 17, 113–126. [CrossRef]
4. Ibraheem, D.; Elaissari, A.; Fessi, H. Gene therapy and DNA delivery systems. Int. J. Pharm. 2014, 459, 70–83.
[CrossRef] [PubMed]
5. Idowu, T.; Samadder, P.; Arthur, G.; Schweizer, F. Design, synthesis and antitumor properties of glycosylated
antitumor ether lipid (GAEL)-chlorambucil-hybrids. Chem. Phys. Lipids 2016, 194, 139–148. [CrossRef]
[PubMed]
6. Andey, T.; Sudhakar, G.; Marepally, S.; Patel, A.; Banerjee, R.; Singh, M. Lipid nanocarriers of a
lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against
triple-negative breast cancer: Pharmacokinetic and efficacy evaluation. Mol. Pharm. 2015, 12, 1105–1120.
[CrossRef]
Pharmaceutics 2019, 11, 115 17 of 19
7. Cardoso, A.M.; Morals, C.M.; Cruz, A.R.; Silva, S.G.; do Vale, M.L.; Marques, E.F.; de Lima, M.C.P.;
Jurado, A.S. New serine-derived gemini surfactants as gene delivery systems. Eur. J. Pharm. Biopharm. 2015,
89, 347–356. [CrossRef]
8. Pattni, B.S.; Chupin, V.V.; Torchilin, V.P. New Developments in Liposomal Drug Delivery. Chem. Rev. 2015,
115, 10938–10966. [CrossRef]
9. Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery.
J. Control. Release 2006, 114, 100–109. [CrossRef]
10. Alvarez-Paino, M.; Munoz-Bonilla, A.; Fernandez-Garcia, M. Antimicrobial Polymers in the Nano-World.
Nanomaterials 2017, 7, 48. [CrossRef]
11. Hemeg, H.A. Nanomaterials for alternative antibacterial therapy. Int. J. Nanomed. 2017, 12, 8211–8225.
[CrossRef] [PubMed]
12. Luo, C.; Miao, L.; Zhao, Y.; Musetti, S.; Wang, Y.H.; Shi, K.; Huang, L. A novel cationic lipid with intrinsic
antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials 2016, 102, 239–248. [CrossRef]
[PubMed]
13. Duhem, N.; Danhier, F.; Preat, V. Vitamin E-based nanomedicines for anti-cancer drug delivery. J. Control.
Release 2014, 182, 33–44. [CrossRef] [PubMed]
14. Koudelka, S.; Turanek Knotigova, P.; Masek, J.; Prochazka, L.; Lukac, R.; Miller, A.D.; Neuzil, J.; Turanek, J.
Liposomal delivery systems for anti-cancer analogues of vitamin E. J. Control. Release 2015, 207, 59–69.
[CrossRef]
15. Neophytou, C.M.; Constantinou, A.I. Drug Delivery Innovations for Enhancing the Anticancer Potential of
Vitamin E Isoforms and Their Derivatives. BioMed Res. Int. 2015, 2015, 584862. [CrossRef] [PubMed]
16. Kievit, F.M.; Zhang, M.Q. Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery
Across Biological Barriers. Adv. Mater. 2011, 23, H217–H247. [CrossRef] [PubMed]
17. Gupta, I.; Sehgal, R.; Kanwar, R.K.; Punj, V.; Kanwar, J.R. Nanocapsules loaded with iron-saturated bovine
lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism.
Nanomedicine 2015, 10, 1289–1314. [CrossRef]
18. Hyvonen, Z.; Plotniece, A.; Reine, I.; Chekavichus, B.; Duburs, G.; Urtti, A. Novel cationic amphiphilic
1,4-dihydropyridine derivatives for DNA delivery. Biochim. Biophys. Acta Biomembr. 2000, 1509, 451–466.
[CrossRef]
19. Pajuste, K.; Hyvonen, Z.; Petrichenko, O.; Kaldre, D.; Rucins, M.; Cekavicus, B.; Ose, V.; Skrivele, B.;
Gosteva, M.; Morin-Picardat, E.; et al. Gene delivery agents possessing antiradical activity: Self-assembling
cationic amphiphilic 1,4-dihydropyridine derivatives. New J. Chem. 2013, 37, 3062–3075. [CrossRef]
20. Petrichenko, O.; Rucins, M.; Vezane, A.; Timofejeva, I.; Sobolev, A.; Cekavicus, B.; Pajuste, K.; Plotniece, M.;
Gosteva, M.; Kozlovska, T.; et al. Studies of the physicochemical and structural properties of self-assembling
cationic pyridine derivatives as gene delivery agents. Chem. Phys. Lipids 2015, 191, 25–37. [CrossRef]
[PubMed]
21. Cindric, M.; Cipak, A.; Serly, J.; Plotniece, A.; Jaganjac, M.; Mrakovcic, L.; Lovakovic, T.; Dedic, A.; Soldo, I.;
Duburs, G.; et al. Reversal of multidrug resistance in murine lymphoma cells by amphiphilic dihydropyridine
antioxidant derivative. Anticancer Res. 2010, 30, 4063–4069. [PubMed]
22. Rucins, M.; Kaldre, D.; Pajuste, K.; Fernandes, M.A.S.; Vicente, J.A.F.; Klimaviciusa, L.; Jaschenko, E.;
Kanepe-Lapsa, I.; Shestakova, I.; Plotniece, M.; et al. Synthesis and studies of calcium channel blocking and
antioxidant activities of novel 4-pyridinium and/or N-propargyl substituted 1,4-dihydropyridine derivatives.
Comptes Rendus Chim. 2014, 17, 69–80. [CrossRef]
23. Jansone, B.; Kadish, I.; van Groen, T.; Beitnere, U.; Plotniece, A.; Pajuste, K.; Klusa, V. Memory-enhancing and
brain protein expression-stimulating effects of novel calcium antagonist in Alzheimer’s disease transgenic
female mice. Pharm. Res 2016, 113, 781–787. [CrossRef] [PubMed]
24. Jansone, B.; Kadish, I.; van Groen, T.; Beitnere, U.; Moore, D.R.; Plotniece, A.; Pajuste, K.; Klusa, V.
A Novel 1,4-Dihydropyridine Derivative Improves Spatial Learning and Memory and Modifies Brain
Protein Expression in Wild Type and Transgenic APP(SweDI) Mice. PLoS ONE 2015, 10, e0127686. [CrossRef]
[PubMed]
25. Tirzite, D.; Koronova, J.; Plotniece, A. Influence of some quaternised 1,4-dihydropyridine derivatives on
liposomes and erythrocyte membranes. Biochem. Mol. Biol. Int. 1998, 45, 849–856. [PubMed]
Pharmaceutics 2019, 11, 115 18 of 19
26. Rucins, M.; Gosteva, M.; Domracheva, I.; Kanepe-Lapsa, I.; Belyakov, S.; Plotniece, M.; Pajuste, K.;
Cekavicus, B.; Jekabsone, M.; Sobolev, A.; et al. Synthesis and Evaluation of Reducing Capacity and
Calcium Channel Blocking Activity of Novel 3,5-Dipropargylcarbonyl-Substituted 1,4-Dihydropyridines.
Chem. Heterocycl. Compd. 2015, 50, 1432–1443. [CrossRef]
27. Stokes, W.S.; Casati, S.; Strickland, J.; Paris, M. Neutral red uptake cytotoxicity tests for estimating starting
doses for acute oral toxicity tests. Curr. Protoc. Toxicol. 2008, 36, 24.
28. ICCVAM. NIH Publication No 07-4519. Research Triangle Park, NC, USA; 2006. Available online: http:
//iccvamniehsnihgov/S (accessed on 20 January 2007).
29. ICCVAM. Background Review Document: In Vitro Basal Cytotoxicity Test Methods for Estimating Acute Oral
Systemic Toxicity; National Institute for Environmental Health Sciences: Research Triangle Park, NC, USA,
2006. Available online: http://iccvam.niehs.nih.gov/methods/acutetox/inv_nru_brd.htm (accessed on 28
January 2019).
30. Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on
classification, labelling and packaging of substances and mixtures, amending and repealing Directives
67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (Text with EEA relevance).
Available online: http://data.europa.eu/eli/reg/2008/1272/2017-01-01 (accessed on 28 January 2019).
31. Suppi, S.; Kasemets, K.; Ivask, A.; Kunnis-Beres, K.; Sihtmae, M.; Kurvet, I.; Aruoja, V.; Kahru, A. A novel
method for comparison of biocidal properties of nanomaterials to bacteria, yeasts and algae. J. Hazard. Mater.
2015, 286, 75–84. [CrossRef]
32. Entian, K.-D.; Kötter, P. 23 Yeast Mutant and Plasmid Collections. In Methods in Microbiology; Brown, A.J.P.,
Tuite, M., Eds.; Academic Press: Cambridge, MA, USA, 1998; Volume 26, pp. 431–449.
33. Metsalu, T.; Vilo, J. ClustVis: A web tool for visualizing clustering of multivariate data using Principal
Component Analysis and heatmap. Nucleic Acids Res. 2015, 43, W566–W570. [CrossRef]
34. Ma, J.Y.; Ma, J.K.; Weber, K.C. Fluorescence studies of the binding of amphiphilic amines with phospholipids.
J. Lipid Res. 1985, 26, 735–744.
35. Joondan, N.; Jhaumeer-Laulloo, S.; Caumul, P. A study of the antibacterial activity of l-Phenylalanine
and l-Tyrosine esters in relation to their CMCs and their interactions with 1,2-dipalmitoyl-sn-glycero-
3-phosphocholine, DPPC as model membrane. Microbiol. Res. 2014, 169, 675–685. [CrossRef]
36. Topel, Ö.; Çakır, B.A.; Budama, L.; Hoda, N. Determination of critical micelle concentration of polybutadiene-
block-poly(ethyleneoxide) diblock copolymer by fluorescence spectroscopy and dynamic light scattering.
J. Mol. Liq. 2013, 177, 40–43. [CrossRef]
37. Hantzsch, A. Ueber die Synthese pyridinartiger Verbindungen aus Acetessigäther und Aldehydammoniak.
Justus Liebigs Ann. Chem. 1882, 215, 1–82. [CrossRef]
38. Makarova, N.V.; Koronova, Z.V.; Plotnietse, A.V.; Tirzite, D.Y.; Tirzit, G.D.; Duburs, G.Y. Synthesis of
1,4-dihydropyridines having an N-alkylpyridinium substituent at the 4-position and their affinity towards
liposomal membranes. Chem. Heterocycl. Compd. 1995, 31, 969–973. [CrossRef]
39. Makarova, N.V.; Plotnietse, A.; Tirzitis, G.; Turovskii, I.; Dubur, G. Some transformations of N-ethoxycarbonyl-
methylpyridinium bromides with a pyridyl or 1,4-dihydropyridyl substituent at position 3. Chem. Heterocycl.
Compd. 1997, 33, 175–183. [CrossRef]
40. Spielmann, H.; Grune, B.; Liebsch, M.; Seiler, A.; Vogel, R. Successful validation of in vitro methods in
toxicology by ZEBET, the National Centre for Alternatives in Germany at the BfR (Federal Institute for Risk
Assessment). Exp. Toxicol. Pathol. 2008, 60, 225–233. [CrossRef]
41. Jolliffe, I.T.; Cadima, J. Principal component analysis: A review and recent developments. Philos. Trans. R.
Soc. A Math. Phys. Eng. Sci. 2016, 374, 20150202. [CrossRef]
42. Bro, R.; Smilde, A.K. Principal component analysis. Anal. Methods 2014, 6, 2812–2831. [CrossRef]
43. Egorova, K.S.; Ananikov, V.P. Toxicity of ionic liquids: Eco(cyto)activity as complicated, but unavoidable
parameter for task-specific optimization. ChemSusChem 2014, 7, 336–360. [CrossRef]
44. Sharma, V.K.; Mukhopadhyay, R. Deciphering interactions of ionic liquids with biomembrane. Biophys. Rev.
2018, 10, 721–734. [CrossRef]
45. Cortesi, R.; Esposito, E.; Menegatti, E.; Gambari, R.; Nastruzzi, C. Effect of cationic liposome composition on
in vitro cytotoxicity and protective effect on carried DNA. Int. J. Pharm. 1996, 139, 69–78. [CrossRef]
46. Singh, R.P.; Gangadharappa, H.V.; Mruthunjaya, K. Phospholipids: Unique carriers for drug delivery systems.
J. Drug Deliv. Sci. Technol. 2017, 39, 166–179. [CrossRef]
Pharmaceutics 2019, 11, 115 19 of 19
47. Joondan, N.; Caumul, P.; Akerman, M.; Jhaumeer-Laulloo, S. Synthesis, micellisation and interaction of
novel quaternary ammonium compounds derived from l-Phenylalanine with 1,2-dipalmitoyl-sn-glycero-
3-phosphocholine as model membrane in relation to their antibacterial activity, and their selectivity over
human red blood cells. Bioorg. Chem. 2015, 58, 117–129.
48. Castillo, J.A.; Pinazo, A.; Carilla, J.; Infante, M.R.; Alsina, M.A.; Haro, I.; Clapés, P. Interaction of Antimicrobial
Arginine-Based Cationic Surfactants with Liposomes and Lipid Monolayers. Langmuir 2004, 20, 3379–3387.
[CrossRef]
49. Matyszewska, D.; Tappura, K.; Orädd, G.; Bilewicz, R. Influence of Perfluorinated Compounds on the
Properties of Model Lipid Membranes. J. Phys. Chem. B 2007, 111, 9908–9918. [CrossRef]
50. Chibowski, E.; Szczes´, A. Zeta potential and surface charge of DPPC and DOPC liposomes in the presence of
PLC enzyme. Adsorption 2016, 22, 755–765. [CrossRef]
51. Muhamadejev, R.; Petrova, M.; Smits, R.; Plotniece, A.; Pajuste, K.; Duburs, G.; Liepinsh, E. Study
of interactions of mononucleotides with 1,4-dihydropyridine vesicles using NMR and ITC techniques.
New J. Chem. 2018. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Institute of Solid State Physics, University of Latvia as the Center of Excellence has received funding from
the European Union’s Horizon 2020 Framework Programme H2020-WIDESPREAD-01-2016-2017-
TeamingPhase2 under grant agreement No. 739508, project CAMART²
